Trials / Completed
CompletedNCT01506193
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 716 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 13 Months – 15 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' investigational measles, mumps, rubella and varicella (MMRV) vaccine (GSK208136, PriorixTetra™) when co-administered along with conjugated Meningococcal C (MenC) vaccine (Meningitec®, Nuron Biotechs' Vaccine) in healthy children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PriorixTetra™ | One dose administered subcutaneously |
| BIOLOGICAL | Meningitec | One dose administered intramuscularly |
Timeline
- Start date
- 2012-02-06
- Primary completion
- 2014-02-17
- Completion
- 2014-03-31
- First posted
- 2012-01-09
- Last updated
- 2018-08-17
- Results posted
- 2017-01-09
Locations
13 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01506193. Inclusion in this directory is not an endorsement.